Edwards Lifesciences (EW), a maker of heart valves, has surpassed Wall Street’s earnings estimates every quarter for more than two years. The Irvine, Calif.-based company announced in late July that Q2 profit rose 28% to $1.13 a share, beating forecasts by 8 cents. Sales growth slowed for the third straight quarter, but the 7% gain to $616.8 million topped views.